Sign in →

Test ID FMPP Myocarditis/Pericarditis Panel

Profile Information

Test ID Reporting Name Available Separately Always Performed
CXB_1 Coxsackie B(1-6) Antibodies, S Yes, (Order COXB) Yes
ECH_1 Echovirus Antibody Panel, Serum Yes, (Order ECHO) Yes
FINFL Influenza Types A and B Ab, Serum No Yes
FCPAB Chlamydophila pneumoniae Ab IgG/M/A No Yes

Method Name

Complement Fixation (CF)/Immunoflourescence Assay (IFA)

Reporting Name

Myocarditis/Pericarditis Panel

Specimen Type

Serum

Container/Tube:

Preferred: Red top

Acceptable: Serum gel

Specimen Volume: 3 mL

Specimen Minimum Volume

2 mL

Specimen Stability Information

Specimen Type Temperature Time
Serum Refrigerated (preferred) 14 days
  Frozen  30 days
  Ambient  7 days

Reference Values

MYOCARDITIS-PERICARDITIS PANEL

 

 COXSACKIE B(1-6) ANTIBODIES, SERUM

 

    REFERENCE RANGE: <1:8

      

    INTERPRETIVE CRITERIA:  

                 <1:8  Antibody Not Detected

                 ≥ 1:8  Antibody Detected

      

Single titers of ≥ 1:32 are indicative of recent infection. Titers of 1:8 or 1:16 may be indicative of either past or recent infection, since CF antibody levels persist for only a few months. A four-fold or greater increase in titer between acute and convalescent specimens confirms the diagnosis. There is considerable crossreactivity among enteroviruses; however, the highest titer is usually associated with the infecting serotype.

 

This test was developed and its performance characteristics have been determined by Focus Diagnostics. Performance characteristics refer to the analytical performance of the test.

 

 ECHOVIRUS ANTIBODIES, SERUM

    

     REFERENCE RANGE: <1:8

      

     INTERPRETIVE CRITERIA:  

                       <1:8  Antibody Not Detected

                       ≥ 1:8  Antibody Detected

      

Single titers ≥ 1:32 are indicative of recent infection. Titers of 1:8 and 1:16 may be indicative of either past or recent infection, since CF antibody levels persist for only a few months. A four-fold or greater increase in titer between acute and convalescent specimens confirms the diagnosis. There is considerable crossreactivity among enteroviruses; however, the highest titer is usually associated with the infecting serotype.

 

      This test was developed and its performance characteristics have been determined by Focus Diagnostics. Performance characteristics refer to the analytical performance of the test.

 

 INFLUENZA TYPES A AND B ANTIBODIES, SERUM

 

     REFERENCE RANGE: <1:8

      

     INTERPRETIVE CRITERIA:

       <1:8 Antibody Not Detected

       ≥ 1:8 Antibody Detected

      

Single titers of ≥ 1:64 are indicative of recent infection. Titers of 1:8 to 1:32 may be indicative of either past or recent infection, since CF antibody levels persist for only a few months. A four-fold or greater increase in titer between acute and convalescent specimens confirms the diagnosis.

 

This test was developed and its performance characteristics have been determined by Focus Diagnostics. Performance characteristics refer to the analytical performance of the test.

 

CHLAMYDOPHILA PNEUMONIAE ANTIBODIES (IgG,

IgA, IgM)

 

     REFERENCE RANGE: IgG <1:64

                                        IgA <1:16

                                        IgM <1:10

 

The immunofluorescent detection of specific antibodies to Chlamydophila pneumoniae may be complicated by cross-reactive antibodies, non-specific antibody stimulation, or past exposure to similar organisms such as C. psittaci and Chlamydia trachomatis. IgM titers of 1:10 or greater usually indicate recent infection, and any IgG titer may indicate past exposure. IgA is typically present at low titers during primary infection, but may be elevated in recurrent exposures or in chronic infection.

 

These assays were developed and their performance characteristics have been determined by Focus Diagnostics. They have not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. Performance characteristics refer to the analytical performance of the test.

  

Day(s) Performed

Varies; Monday through Saturday

Report Available

1 - 5 days

Performing Laboratory

Focus Diagnositics, Inc.

Test Classification

These assays were developed and their performance characteristics have been determined by Focus Diagnostics. They have not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. Performance characteristics refer to the analytical performance of the test.

CPT Code Information

86658 x 11-Enterovirus

86710 x 2-Antibody; influenza virus

86331 x 2-Immunodiffusion

86632-Chlamydia, IgM

NY State Approved

Yes